These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 34625531)

  • 1. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
    Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
    Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional role of SGK3 in PI3K/Pten driven liver tumor development.
    Cao H; Xu Z; Wang J; Cigliano A; Pilo MG; Ribback S; Zhang S; Qiao Y; Che L; Pascale RM; Calvisi DF; Chen X
    BMC Cancer; 2019 Apr; 19(1):343. PubMed ID: 30975125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade.
    Wang C; Che L; Hu J; Zhang S; Jiang L; Latte G; Demartis MI; Tao J; Gui B; Pilo MG; Ribback S; Dombrowski F; Evert M; Calvisi DF; Chen X
    Liver Int; 2016 Aug; 36(8):1176-86. PubMed ID: 26716908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.
    Shang R; Song X; Wang P; Zhou Y; Lu X; Wang J; Xu M; Chen X; Utpatel K; Che L; Liang B; Cigliano A; Evert M; Calvisi DF; Chen X
    Gut; 2021 Sep; 70(9):1746-1757. PubMed ID: 33144318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASSF1A independence and early galectin-1 upregulation in PIK3CA-induced hepatocarcinogenesis: new therapeutic venues.
    Scheiter A; Evert K; Reibenspies L; Cigliano A; Annweiler K; Müller K; Pöhmerer LM; Xu H; Cui G; Itzel T; Materna-Reichelt S; Coluccio A; Honarnejad K; Teufel A; Brochhausen C; Dombrowski F; Chen X; Evert M; Calvisi DF; Utpatel K
    Mol Oncol; 2022 Mar; 16(5):1091-1118. PubMed ID: 34748271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic actions of Alpelisib and Melatonin in breast cancer cell lines with PIK3CA gene mutation.
    de Godoy BLV; Moschetta-Pinheiro MG; Chuffa LGA; Pondé NF; Reiter RJ; Colombo J; Zuccari DAPC
    Life Sci; 2023 Jul; 324():121708. PubMed ID: 37086897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway.
    Xu Z; Hu J; Cao H; Pilo MG; Cigliano A; Shao Z; Xu M; Ribback S; Dombrowski F; Calvisi DF; Chen X
    Exp Mol Med; 2018 Jan; 50(1):e417. PubMed ID: 29303510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A selective c-Met and Trks inhibitor Indo5 suppresses hepatocellular carcinoma growth.
    Luo T; Zhang SG; Zhu LF; Zhang FX; Li W; Zhao K; Wen XX; Yu M; Zhan YQ; Chen H; Ge CH; Gao HY; Wang L; Yang XM; Li CY
    J Exp Clin Cancer Res; 2019 Mar; 38(1):130. PubMed ID: 30885237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
    Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
    J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
    Passarelli A; Carbone V; Pignata S; Mazzeo R; Lorusso D; Scambia G; Canova S; Di Palma T; Tasca G; Mantiero M; Naglieri E; Andreetta C; Rauso M; Brunetti AE; Laera L; Abeni C; Scandurra G; Gambaro AR; Pastore A; Bengala C; Gunnellini M; Farolfi A; Spinello M; Bartoletti M
    Gynecol Oncol; 2024 Apr; 183():61-67. PubMed ID: 38518529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
    Gökmen-Polar Y; Liu Y; Toroni RA; Sanders KL; Mehta R; Badve S; Rommel C; Sledge GW
    Breast Cancer Res Treat; 2012 Dec; 136(3):673-82. PubMed ID: 23085766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic efficacy of FASN inhibition in preclinical models of HCC.
    Wang H; Zhou Y; Xu H; Wang X; Zhang Y; Shang R; O'Farrell M; Roessler S; Sticht C; Stahl A; Evert M; Calvisi DF; Zeng Y; Chen X
    Hepatology; 2022 Oct; 76(4):951-966. PubMed ID: 35076948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
    Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
    BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.
    Song X; Liu X; Wang H; Wang J; Qiao Y; Cigliano A; Utpatel K; Ribback S; Pilo MG; Serra M; Gordan JD; Che L; Zhang S; Cossu A; Porcu A; Pascale RM; Dombrowski F; Hu H; Calvisi DF; Evert M; Chen X
    Clin Cancer Res; 2019 Jan; 25(1):403-413. PubMed ID: 30084835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA.
    Garay JP; Smith R; Devlin K; Hollern DP; Liby T; Liu M; Boddapati S; Watson SS; Esch A; Zheng T; Thompson W; Babcock D; Kwon S; Chin K; Heiser L; Gray JW; Korkola JE
    Breast Cancer Res; 2021 Aug; 23(1):81. PubMed ID: 34344439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
    Ohta K; Hoshino H; Wang J; Ono S; Iida Y; Hata K; Huang SK; Colquhoun S; Hoon DS
    Oncotarget; 2015 Feb; 6(5):3211-24. PubMed ID: 25633810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
    Ladu S; Calvisi DF; Conner EA; Farina M; Factor VM; Thorgeirsson SS
    Gastroenterology; 2008 Oct; 135(4):1322-32. PubMed ID: 18722373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
    Bollard J; Miguela V; Ruiz de Galarreta M; Venkatesh A; Bian CB; Roberto MP; Tovar V; Sia D; Molina-Sánchez P; Nguyen CB; Nakagawa S; Llovet JM; Hoshida Y; Lujambio A
    Gut; 2017 Jul; 66(7):1286-1296. PubMed ID: 27849562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.